Semaglutide
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Semaglutide?
The active ingredient in Wegovy, Ozempic (pen and tablets) and Rybelsus, which Ozempic tablets are replacing in the US.
Its roughly seven-day half-life is what allows weekly injection. When a seller lists “semaglutide” at a fraction of brand pricing, they mean a compounded preparation of this molecule, not the approved product, and their pricing page often blurs the difference.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Semaglutide comes up on this site
On GLP Watchdog, Semaglutide comes up in 277 research articles, 648 seller reviews, 149 FDA warning letters and 4 tools. Browse the FDA warning letters.
Research that discusses it
- Compounded Semaglutide and Tirzepatide Are Ending: What to Do Next
- Generic GLP-1s: Eleven for Liraglutide, and None You Can Buy for Semaglutide
- Compounded Semaglutide vs Ozempic and Wegovy: What Is Actually Different
- Why Compounded Semaglutide Is Mixed With B12
- BPC-157, MOTS-c and Other Peptides With Semaglutide or Tirzepatide
- Bimagrumab Plus Semaglutide: The Muscle Question
- All 277 articles are on the research page
Drug pages
Tools that use it
Seller reviews that mention it
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers